Takeda Collaborates with Codexis to Advance Novel Gene Therapies for Rare Genetic Disorders

 Takeda Collaborates with Codexis to Advance Novel Gene Therapies for Rare Genetic Disorders

Takeda Collaborates with Codexis to Advance Novel Gene Therapies for Rare Genetic Disorders

Shots:

  • Codexis to receive an upfront payment, reimbursement for research and development fees, development and commercial milestones along with royalties on sales of any commercial product developed under the collaboration
  • The alliance will initially work on three programs to develop novel gene therapies for lysosomal storage disorders and blood factor deficiencies. Codexis will create the novel enzyme sequences for advancement as gene therapies into pre-clinical development utilizing its CodeEvolver protein engineering platform
  • Takeda is responsible for the pre/ clinical development and commercialization of gene therapy products resulting from the collaboration programs. In addition to three initial programs, Takeda may extend it up to four additional programs for other indications

Click here­ to­ read full press release/ article | Ref: GlobeNewswire | Image: Owler

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post